

HPV Vaccine May Lead to Infection with High Risk Strains; CBCD Reviews Medical Evidence

"Vaccinated women had a higher prevalence of non-vaccine high-risk types than unvaccinated women." (1)

ROCHESTER, NEW YORK, UNITED STATES, May 8, 2015 /EINPresswire.com/ --

"Infected with the human papillomavirus (HPV)? We recommend taking <u>Novirin</u> or <u>Gene-Eden-VIR</u>." - Greg Bennett, CBCD

A new study found that women, who received the original Gardasil vaccine, may harbor a high risk HPV strain. Dr. Guo and colleagues found that "women in the study who received the Gardasil vaccine were, indeed, less likely to be infected with the four strains of the virus included in the vaccine ... however, the women who received the vaccine were more likely to be infected with other highrisk HPV strains not included in the vaccine. About 61 percent of the women who received the vaccine were infected with another type of high-risk HPV, compared with 40 percent of women who did not receive the vaccine." (2)

The public should be reminded that according to the HPV vaccine website, "Gardasil may not fully protect everyone, nor will it protect against diseases caused by other HPV types or against diseases not caused by HPV. Gardasil does not prevent all types of cervical cancer, so future cervical cancer screenings will be important for your daughter. Gardasil does not treat cervical





cancer or genital warts." (3)

Center for the Biology of Chronic Disease (CBCD) therefore recommends that women infected with the latent HPV virus take Gene-Eden-VIR or Novirin. The formula of these natural antiviral products was shown to reduce symptoms associated with HPV

Click to learn more about HPV symptoms.

The formula of Gene-Eden-VIR and Novirin was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin and Gene-Eden-VIR formula is effective against the HPV and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, "individuals infected with the HPV...reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR." (4) The study authors also wrote that "we observed a statistically significant decrease in the severity, duration, and frequency of symptoms." (4)

Both products can be ordered online on the Gene-Eden-VIR and Novirin websites here:

http://www.novirin.com

and

http://www.gene-eden-vir.com

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

Note: Novirin has the same formula as Gene-Eden-VIR. However, it contains higher quality and more expensive ingredients.

In light of the above information, it is also important to note that a new version of Gardasil was approved on December 2014 by the FDA. According to the makers of the vaccine, Gardasil 9 is effective against 9 strains of HPV. This is compared to the original Gardasil, which only covered 4 strains of the virus. The study that led to the vaccine's approval included 14,215 women. The researchers reported that Gardasil 9 prevented cervical, vulvar and vaginal disease associated with HPV-31, 33, 45, 52 and 58 as well as the HPV types covered by the older version, 6, 11, 16 and 18. (5) Importantly, Dr. Elmar A. Joura and colleagues wrote that Gardasil 9 "did not prevent infection and disease related to HPV types beyond the nine types covered by the vaccine." (5) The new formulation was developed by Merck Pharmaceuticals (MRK). Merck Pharmaceuticals also funded the study.

"We at the Center agree that the fact that Gardasil 9 is effective against 5 more strains of the HPV virus is a step forward against HPV infection. However, clearly, neither the original Gardasil, nor the new Gardasil 9, can protect against all HPV types. Moreover, the American public should be aware that to date, there are no vaccines that prevent disease in those who are already infected." - Greg Bennett, CBCD

Neither vaccine treats cervical cancer or genital warts. (3)

In addition to the HPV vaccine, what treatments are available against HPV infection?

"There are no drugs approved against the HPV. Current treatments include procedures, such as

cryotherapy, conization, and the Loop Electrosurgical Excision Procedure (LEEP). These procedures use liquid nitrogen, a surgical knife (scalpel), a carbon dioxide (CO2) laser, or electrical current to remove the abnormal growths caused by the HPV. These growths include cells that harbor the active virus. The procedures do not target cells with the latent virus. Since they do not remove the latent virus, these procedures only produce a temporary remission." (4) In contrast, Novirin and Gene-Eden-VIR were designed to help the immune system to target the latent HPV.

All orders of Gene-Eden-VIR and Novirin are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

- (1) Fangjian Guo, Jacqueline M. Hirth, Abbey B. Berenson "Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years." Presentation Abstract. American Association for Cancer Research. Presented April 19, 2015. <a href="http://www.abstractsonline.com/plan/ViewAbstract.aspx?mlD=3682&sKey=7f019f73-accb-484e-becc-5ecc405f8ec5&cKey=e2313b32-d6ac-4443-ab2d-49c368ea3b89&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424
- (2) Rettner, R. "Women who received HPV vaccine may need another shot." April 23, 2015 CBS News http://www.cbsnews.com/news/women-who-received-hpv-vaccine-may-need-another-shot/
- (3) Gardasil.com http://www.gardasil.com/about-gardasil/
- (4) Polansky H, Itzkovitz E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Pharmacology & Pharmacy, 2013, 4, 1-8 http://dx.doi.org/10.4236/pp.2013.46A001
- (5) Elmar A. Joura, M.D., Anna R. Giuliano, Ph.D., Ole-Erik Iversen, M.D., Celine Bouchard, M.D., Constance Mao, M.D., Jesper Mehlsen, M.D., Edson D. Moreira, Jr., M.D., Yuen Ngan, M.D., Lone Kjeld Petersen, M.D., Eduardo Lazcano-Ponce, M.D., Punnee Pitisuttithum, M.D., Jaime Alberto Restrepo, M.D., Gavin Stuart, M.D., Linn Woelber, M.D., Yuh Cheng Yang, M.D., Jack Cuzick, Ph.D., Suzanne M. Garland, M.D., Warner Huh, M.D., Susanne K. Kjaer, M.D., Oliver M. Bautista, Ph.D., Ivan S.F. Chan, Ph.D., Joshua Chen, Ph.D., Richard Gesser, M.D., Erin Moeller, M.P.H., Michael Ritter, B.A., Scott Vuocolo, Ph.D., and Alain Luxembourg, M.D., Ph.D. for the Broad Spectrum HPV Vaccine Study "A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women." The New England Journal of Medicine. Published February 19, 2015. http://www.nejm.org/doi/full/10.1056/NEJMoa1405044

Hanan Polansky Lilac Corp. 5852509999 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2015 IPD Group, Inc. All Right Reserved.